ain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy.

reatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of c. difficile. c. difficile produces toxins a and b which contribute to the development of cdad. hypertoxin producing strains of c. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. cdad must be considered in all patients who present with diarrhea following antibiotic use. careful medical history is necessary since cdad has been reported to occur over two months after the administration of antibacterial agents. if cdad is suspected or confirmed, ongoing antibiotic use not directed against c. difficile may need to be discontinued. appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of c. difficile, and surgical evaluation should be instituted as clinically indicated.

or pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. for other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. in the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil should be administered for at least 10 days. renal impairment in patients with renal impairment, the dosage of cefadroxil should be adjusted according to creatinine clearance rates to prevent drug accumulation. the following schedule is suggested. in adults, the initial dose is 1000 mg of cefadroxil and the maintenance dose (based on the creatinine clearance rate [ml/min/1.73 m2]) is 500 mg at the time intervals listed below. creatinine clearances dosage interval 0 to 10 ml/min 36 hours 10 to 25 ml/min 24 hours 25 to 50 ml/min 12 hours patients with creatinine clearance rates over 50 ml/min may be treated as if they were patients having normal renal function.

ed for cephalosporin-class antibiotics: toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive coombs’ test, increased bun, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (ast), elevated alanine aminotransferase (alt), elevated bilirubin, elevated ldh, eosinophilia, pancytopenia, neutropenia. several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see dosage and administration and overdosage). if seizures associated with drug therapy occur, the drug should be discontinued. anticonvulsant therapy can be given if clinically indicated.

ci staphylococci, including penicillinase-producing strains streptococcus (diplococcus) pneumoniae escherichia coli proteus mirabilis klebsiella species moraxella (branhamella) catarrhalis note: most strains of enterococcus faecalis (formerly streptococcus faecalis) and enterococcus faecium(formerly streptococcus faecium) are resistant to cefadroxil. it is not active against most strains of enterobacter species, morganella morganii (formerly proteus morganii), and p. vulgaris. it has no activity against pseudomonas species and acinetobacter calcoaceticus (formerly mima and herelleaspecies). susceptibility testing for specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by fda for this drug, please see: https://www.fda.gov/stic.